Key Highlights

  • Diaceutics Plc (LSE:DXRX) shares advanced 3.37% on 6 October 2026.
  • First-half 2026 Revenue rose 22% at constant currency to £17.5 million.
  • Annual Recurring Revenue jumped 79% to £29.4 million, and the order book grew 38% to £43.7 million.
  • The company reported 107% visibility on FY26 median consensus revenue as of 31 August 2026.

Diaceutics Shares Climb 3.37% on 6 October 2026

Diaceutics Plc (LSE:DXRX), the Belfast-based technology and solutions provider to the pharmaceutical and biotech industry, closed the 6 October 2026 session up 3.37%. No new company announcement was identified for the day. The move appears to reflect continued investor confidence following the company's interim results in September, which showed a sharp increase in recurring revenue and better-than-full visibility on full-year revenue expectations.

Diaceutics shares had come under pressure earlier in 2026, including a near 9% fall in May when full-year 2025 results were published. The latest figures have helped rebuild sentiment.

What Diaceutics Does

Diaceutics helps pharmaceutical and biotech companies commercialise precision medicines, treatments that depend on a diagnostic test to identify the right patients. Through its DXRX platform, data analytics, scientific and advisory services, the company works to ensure that patients receive the right test and the right therapy.

The company supported 18 of the top 20 global pharmaceutical companies in the first half of 2026, serving 55 customers across 103 therapeutic brands. This reach gives Diaceutics deep insight into diagnostic testing patterns and a leading position in a specialised niche.

Interim Results Show Recurring Revenue Momentum

For the six months to 30 June 2026, revenue grew 22% at constant currency to £17.5 million. The headline figure that caught investors' attention was annual recurring revenue, which rose 79% to £29.4 million. Recurring revenue recognised in the period grew 42% to £12.5 million. The order book increased 38% to £43.7 million.

Recurring revenue is especially valuable because it provides predictable income and typically commands a higher valuation multiple than project-based work. Diaceutics has been deliberately shifting its Business model towards longer-term, subscription-style contracts, and the first-half figures show that strategy gaining traction.

Visibility Above 100% on Full-Year Expectations

Perhaps the most reassuring element for investors was visibility. As of 31 August 2026, Diaceutics said it had 107% visibility on achieving the median analyst consensus revenue estimate for FY26, based on contracted revenue and the weighted sales pipeline. That compared with 91% visibility at the time of its July trading update. The board said it remains confident in meeting expectations for 2026.

High visibility reduces the risk of a shortfall, which had been a concern after the company described industry-wide challenges and shifting market dynamics in 2025.

Precision For All Expands the Market

A major strategic change is the Precision For All initiative. Historically, Diaceutics focused on around 250 precision medicine therapies. Under the new strategy, the company has expanded its addressable market to more than 1,100 therapies, covering a much broader set of treatments where data and diagnostics can improve commercial outcomes. In the first half, 22% of revenue came from this expanded segment.

The Relay product, formerly called PMx, has also grown, with annual recurring revenue rising from £2.6 million at inception to £4.3 million by June 2026.

Financial Strength

Diaceutics returned to profit in 2025, with a pre-tax profit of £302,000 compared with a £1.9 million loss in 2024. Revenue grew 20% to £38.4 million, and adjusted EBITDA jumped 80% to £7.6 million, lifting the Margin to 20%. The company has no debt, and cash increased in the first half of 2026.

Why Investors Are Watching Diaceutics Plc (LSE:DXRX)

The stock is in focus because it is transitioning into a recurring-revenue business at the same time as it significantly expands its market opportunity. The combination of 79% ARR growth, a growing order book and visibility above 100% gives investors confidence in near-term delivery, while Precision For All offers a longer-term growth narrative. Continued contract wins with large pharma companies are the key catalyst to watch.

Risks to Consider

Diaceutics depends on pharmaceutical spending on commercialisation, which can be affected by drug pipeline delays, pricing pressures and budget cuts. Contract timing can be lumpy. Expanding into a broader set of therapies brings execution risk. As a small-cap company, the shares can be volatile and sensitive to changes in sentiment.

Conclusion

Diaceutics Plc (LSE:DXRX) gained 3.37% on 6 October 2026 as investors continued to respond to its interim results, which showed 22% revenue growth, a 79% rise in annual recurring revenue and 107% visibility on full-year consensus revenue. The Precision For All strategy has broadened the company's opportunity, and the shift to recurring revenue is improving the quality of earnings. Delivery in the second half will be the next test.